What to Expect When Starting Finasteride
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Introduction
Finasteride is a 5-alpha reductase type 2 inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). At 5 mg daily (Proscar), it treats benign prostatic hyperplasia (BPH). At 1 mg daily (Propecia), it treats male androgenetic alopecia (male pattern baldness). Results require months to develop, as DHT suppression gradually allows prostate shrinkage or hair follicle recovery.
Week-by-week timeline
No Immediate Effects — Patience Required
DHT levels fall within weeks, but clinical benefits for BPH or hair loss require months. Do not expect rapid changes. Sexual side effects (reduced libido, erectile dysfunction, reduced ejaculate volume) may appear early. These affect roughly 2-5% of men and are usually reversible upon stopping.
Early Hormonal Adaptation
DHT is reduced by approximately 65-70% (finasteride 5 mg) or 60-70% (1 mg). PSA levels will decrease by approximately 50% over 6 months. For BPH: some patients report mild early urinary improvement. For hair loss: no visible improvement yet — the initial phase involves stabilization of ongoing shedding.
Beginning to See Results
For BPH: meaningful improvement in urinary flow and symptom scores begins at 3-6 months. For hair loss at 1 mg: stabilization of hair loss typically occurs by month 3-6. Some patients report increased shedding in the first 1-3 months — this is temporary as affected follicles transition (do not stop treatment).
Continued Improvement
For BPH: urinary symptoms continue to improve, with maximum benefit at 12-24 months. For hair: initial regrowth becomes visible at 6-12 months in responding patients. About 85% of men stabilize hair loss; about 65% see some regrowth with the 1 mg dose.
Long-Term Maintenance
Stopping finasteride reverses its benefits within months — prostate returns to previous size, and lost hair returns. For ongoing benefit, finasteride must be taken continuously. Annual assessment with your prescriber is recommended.
When to call your doctor
Contact your healthcare provider if you experience:
- Inability to urinate despite being on finasteride (acute urinary retention — seek urological care)
- Breast tenderness or breast enlargement (gynecomastia — rare but possible)
- Symptoms of depression or mood changes (rare association with 5-alpha reductase inhibitors)
- PSA rising on finasteride (must be investigated for prostate cancer)
- Allergic reaction: rash, swelling, difficulty breathing
- Testicular pain or changes
- Persistent sexual side effects after stopping (post-finasteride syndrome — report to your prescriber)
Tips for getting started
Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets — DHT suppression can cause genital abnormalities in male fetuses. If a pregnant woman must handle finasteride, use gloves. PSA must be monitored: finasteride halves PSA, so a PSA of 2 on finasteride corresponds to a true PSA of approximately 4. Report any rising PSA even within the normal range. For hair loss, combine with minoxidil topically for additive benefit. Discuss side effect concerns openly with your prescriber — many men stop unnecessarily due to nocebo effects (side effects caused by expectations).
Frequently asked questions
More about Finasteride
References
- [Regulatory] FDA Label: Propecia (finasteride 1 mg) Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s021lbl.pdf Accessed 2026-03-01.
- [Regulatory] NIH MedlinePlus: Finasteride https://medlineplus.gov/druginfo/meds/a698016.html Accessed 2026-03-01.
- [Regulatory] AUA BPH Guidelines: 5-Alpha Reductase Inhibitors https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline Accessed 2026-03-01.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: